672 related articles for article (PubMed ID: 23763388)
1. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.
Kuhle J; Malmeström C; Axelsson M; Plattner K; Yaldizli O; Derfuss T; Giovannoni G; Kappos L; Lycke J
Acta Neurol Scand; 2013 Dec; 128(6):e33-6. PubMed ID: 23763388
[TBL] [Abstract][Full Text] [Related]
2. A comparative study of CSF neurofilament light and heavy chain protein in MS.
Kuhle J; Plattner K; Bestwick JP; Lindberg RL; Ramagopalan SV; Norgren N; Nissim A; Malaspina A; Leppert D; Giovannoni G; Kappos L
Mult Scler; 2013 Oct; 19(12):1597-603. PubMed ID: 23529999
[TBL] [Abstract][Full Text] [Related]
3. The impact of pre-analytical variables on the stability of neurofilament proteins in CSF, determined by a novel validated SinglePlex Luminex assay and ELISA.
Koel-Simmelink MJ; Vennegoor A; Killestein J; Blankenstein MA; Norgren N; Korth C; Teunissen CE
J Immunol Methods; 2014 Jan; 402(1-2):43-9. PubMed ID: 24275679
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid light and heavy neurofilaments in neuromyelitis optica.
Wang H; Wang C; Qiu W; Lu Z; Hu X; Wang K
Neurochem Int; 2013 Dec; 63(8):805-8. PubMed ID: 24161620
[TBL] [Abstract][Full Text] [Related]
5. A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein.
Kuhle J; Regeniter A; Leppert D; Mehling M; Kappos L; Lindberg RL; Petzold A
J Neuroimmunol; 2010 Mar; 220(1-2):114-9. PubMed ID: 20117845
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal one-year study of levels and stoichiometry of neurofilament heavy and light chain concentrations in CSF in patients with multiple system atrophy.
Petzold A; Thompson EJ; Keir G; Quinn N; Holmberg B; Dizdar N; Wenning GK; Rascol O; Tolosa E; Rosengren L
J Neurol Sci; 2009 Apr; 279(1-2):76-9. PubMed ID: 19195665
[TBL] [Abstract][Full Text] [Related]
7. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis.
Teunissen CE; Iacobaeus E; Khademi M; Brundin L; Norgren N; Koel-Simmelink MJ; Schepens M; Bouwman F; Twaalfhoven HA; Blom HJ; Jakobs C; Dijkstra CD
Neurology; 2009 Apr; 72(15):1322-9. PubMed ID: 19365053
[TBL] [Abstract][Full Text] [Related]
8. Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis.
Fialová L; Bartos A; Svarcová J; Zimova D; Kotoucova J; Malbohan I
J Neuroimmunol; 2013 Sep; 262(1-2):113-20. PubMed ID: 23870535
[TBL] [Abstract][Full Text] [Related]
9. Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.
Axelsson M; Malmeström C; Gunnarsson M; Zetterberg H; Sundström P; Lycke J; Svenningsson A
Mult Scler; 2014 Jan; 20(1):43-50. PubMed ID: 23702432
[TBL] [Abstract][Full Text] [Related]
10. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa.
Kuhle J; Barro C; Andreasson U; Derfuss T; Lindberg R; Sandelius Å; Liman V; Norgren N; Blennow K; Zetterberg H
Clin Chem Lab Med; 2016 Oct; 54(10):1655-61. PubMed ID: 27071153
[TBL] [Abstract][Full Text] [Related]
11. Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis.
Amor S; van der Star BJ; Bosca I; Raffel J; Gnanapavan S; Watchorn J; Kuhle J; Giovannoni G; Baker D; Malaspina A; Puentes F
Mult Scler; 2014 Sep; 20(10):1355-62. PubMed ID: 24515731
[TBL] [Abstract][Full Text] [Related]
12. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein.
Novakova L; Zetterberg H; Sundström P; Axelsson M; Khademi M; Gunnarsson M; Malmeström C; Svenningsson A; Olsson T; Piehl F; Blennow K; Lycke J
Neurology; 2017 Nov; 89(22):2230-2237. PubMed ID: 29079686
[TBL] [Abstract][Full Text] [Related]
13. Ultrasensitive immunoassay allows measurement of serum neurofilament heavy in multiple sclerosis.
Verberk IMW; Koel-Simmelink M; Twaalfhoven H; Vrenken H; Korth C; Killestein J; Teunissen CE; Bridel C
Mult Scler Relat Disord; 2021 May; 50():102840. PubMed ID: 33626430
[TBL] [Abstract][Full Text] [Related]
14. Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS.
Halbgebauer S; Steinacker P; Verde F; Weishaupt J; Oeckl P; von Arnim C; Dorst J; Feneberg E; Mayer B; Rosenbohm A; Silani V; Ludolph AC; Otto M
J Neurol Neurosurg Psychiatry; 2022 Jan; 93(1):68-74. PubMed ID: 34417339
[TBL] [Abstract][Full Text] [Related]
15. Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study.
Petzold A; Eikelenboom MJ; Keir G; Grant D; Lazeron RH; Polman CH; Uitdehaag BM; Thompson EJ; Giovannoni G
J Neurol Neurosurg Psychiatry; 2005 Feb; 76(2):206-11. PubMed ID: 15654034
[TBL] [Abstract][Full Text] [Related]
16. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
[TBL] [Abstract][Full Text] [Related]
17. Assessing tissue damage in multiple sclerosis: a biomarker approach.
Burman J; Zetterberg H; Fransson M; Loskog AS; Raininko R; Fagius J
Acta Neurol Scand; 2014 Aug; 130(2):81-9. PubMed ID: 24571714
[TBL] [Abstract][Full Text] [Related]
18. Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis.
Kuhle J; Leppert D; Petzold A; Regeniter A; Schindler C; Mehling M; Anthony DC; Kappos L; Lindberg RL
Neurology; 2011 Apr; 76(14):1206-13. PubMed ID: 21346223
[TBL] [Abstract][Full Text] [Related]
19. Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis.
Håkansson I; Tisell A; Cassel P; Blennow K; Zetterberg H; Lundberg P; Dahle C; Vrethem M; Ernerudh J
J Neuroinflammation; 2018 Jul; 15(1):209. PubMed ID: 30021640
[TBL] [Abstract][Full Text] [Related]
20. A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation.
Gaetani L; Höglund K; Parnetti L; Pujol-Calderon F; Becker B; Eusebi P; Sarchielli P; Calabresi P; Di Filippo M; Zetterberg H; Blennow K
Alzheimers Res Ther; 2018 Jan; 10(1):8. PubMed ID: 29370869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
